BASF expects Force Majeure to end in Q3

By Nathan Gray contact

- Last updated on GMT

Credit: BASF
Credit: BASF
Global ingredients supplier BASF says it expects to life its Force Majeure on human nutrition products including vitamin A, vitamin E and carotenoids from the middle of Q3 2018.

A fire at the plant on 31st​ October 2017 forced the company to declare a Force Majeure​ on all its citral and aroma-based ingredients – including downstream products like vitamin A, vitamin E and several other carotenoids.

Previous updates​ suggested the plant would re-commence operations in March 2018 at the earliest – with the start-up process is expected to take several weeks, and that production of nutritional ingredients can only re-start after the initial citral plant is fully back in production.

A fresh update from BASF has now confirmed that the company has lifted its force majeure for key vitamin A and E products in its animal nutrition business. However, it will be some time until human nutritional products are back online, it added.

“Due to a more demanding quality testing process relative to its animal nutrition business, BASF expects to lift force majeure for vitamin A and E products as well as carotenoids for its human nutrition business from mid of Q3 2018 onwards, in a step-wise approach,”​ BASF said in a press release.

The firm added that lifting of force majeure for citral and isoprenol-based aroma ingredients is expected in Q4 – noting that time differences are due to different manufacturing steps needed in this production chain relative to its vitamin production.

Geographic impact

The company previously stated that actual availability will ‘strongly depend’ on the product and geographic regions.

Once manufactured, the lead time to ship products to regions differs, taking from a few days or weeks within Europe, to several weeks or months in countries overseas, said BASF.

Related products

show more

Breakthrough in Women's Health

Breakthrough in Women's Health

Biosearch Life | 08-Apr-2019 | Clinical Study

A new study performed on women with polycystic ovary syndrome (PCOS) and fertility problems has been published in Gynecological Endocrinology. Results...

MenaQ7® K2: Patent Protection, Confirmed Benefits

MenaQ7® K2: Patent Protection, Confirmed Benefits

NattoPharma USA, Inc. | 25-Mar-2019 | Data Sheet

Vitamin K2 is the new cardio-support nutrient because clinical studies have confirmed it delivers what no other compound can: reduction in arterial stiffening.

High Protein Snacks: Beyond the Protein Bar

High Protein Snacks: Beyond the Protein Bar

International Dehydrated Foods | 04-Feb-2019 | Technical / White Paper

As snacking becomes more of an ingrained part of the American diet, it will be increasingly important for snacks to deliver nutrition benefits, including...

Clean Label Dietary Supplements - One Perspective

Clean Label Dietary Supplements - One Perspective

Gemini Pharmaceuticals | 01-Feb-2019 | Technical / White Paper

“Clean Label” seems to be all the rage these days. But what does it mean? With no clear regulatory definition, a vacuum has been created where each dietary...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars